Evidence
Panminerva Med. 2023 Sep;65(3):391-399. doi: 10.23736/S0031-0808.23.04850-4.
ABSTRACT
Alcohol consumption (AC) and metabolic syndrome (MS) represent the first cause of liver disease, hepatocellular carcinoma and liver transplantation. The habit of consuming alcoholic beverages and the presence of MS and non-alcoholic fatty liver disease (NAFLD) often coexist in the same patient. The histoclinical boundaries between alcohol related liver disease (ALD) and NAFLD are often not well defined. The co-presence of AC and MS increases the risk of hepatic and extra-hepatic disease. The terminological evolution from NAFLD to metabolic associated fatty liver disease (MAFLD) is certainly a useful advance. However, it is known that the appearance of liver fibrosis increases oncologic and cardiovascular disease risk, which in the case of cirrhosis can be present even in the absence of steatosis and that the mechanisms of fibrogenesis can act independently of the presence of steatosis/steatohepatitis. For this reason, as already stated recently, a further terminological evolution can be hypothesized. This article was originally published with mistakes in the text. The new corrected citable version appears below.
PMID:37750860 | DOI:10.23736/S0031-0808.23.04850-4
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Corrected and republished from: Metabolic associated liver disease
🌐 90 Days
VR Related Evidence Matrix
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Occult liver disease: a multinational perspective
- Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Biopsy Handling of Metabolic-Associated Fatty Liver Disease (MAFLD): the Children's Hospital of Eastern Ontario grossing protocol
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers
- The Global Epidemic of Metabolic Fatty Liver Disease
- Emerging roles of RNA-binding proteins in fatty liver disease
- Metabolic Disorders in Liver Transplant Recipients: The State of the Art
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- COVID-19 in Individuals with Chronic Liver Diseases
- Inflammatory liver diseases and susceptibility to sepsis
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Mass spectrometry imaging-based metabolomics highlights spatial metabolic alterations in three types of liver injuries
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- Costunolide attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Correlation of Grades of Non-alcoholic Fatty Liver on Ultrasound With Blood Parameters
- Liver involvement in presence of heart disease and heart involvement in presence of liver disease: a conundrum
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
Evidence Blueprint
Corrected and republished from: Metabolic associated liver disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Corrected and republished from: Metabolic associated liver disease
🌐 365 Days
VR Related Evidence Matrix
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Fatty liver disease's renaming impacts on drug clinical trials
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Occult liver disease: a multinational perspective
- Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease
- MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Metabolic dysfunction-associated fatty liver disease in people living with HIV
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome
- Role of the angiopoietin-like protein family in the progression of NAFLD
- MBOAT7 in liver and extrahepatic diseases
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- How far are we from an approved drug for non-alcoholic steatohepatitis?
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Liver health and the interplay between obesity, alcohol and bariatric surgery
- Correlation of the Pediatric Metabolic Index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children
- Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study
- How to identify at-risk NAFLD in the primary care setting
- Liver sinusoidal endothelial transcription factors in metabolic homeostasis and disease
- Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation
- Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease
- Towards precision medicine in non-alcoholic fatty liver disease
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Research progress on the histological scoring system for nonalcoholic fatty liver disease
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter
- Type 2 Diabetes Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to Cancer
- Progress in the Treatment of Metabolic-Related Fatty Liver Disease
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- Impacts of Non-alcoholic Fatty Liver Disease on Acute Coronary Syndrome: Evidence and Controversies
- Investigating the correlation between COVID-19 and the progression of chronic liver disease
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis
- Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis
- Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia
- NASH After Liver Transplantation: Impact of Immunosuppression
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Liver fat as risk factor of hepatic and cardiometabolic diseases